Therapeutic treatment methods

Details Therapeutic treatment methods Therapeutic treatment methods

2007-02-12

2009-06-16

Marschel, Ardin (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S176000

Reexamination Certificate

active

07547687

ABSTRACT:
The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.

REFERENCES:
patent: 3001988 (1961-09-01), Nysted
patent: 3001991 (1961-09-01), Allen et al.
patent: 4868167 (1989-09-01), Mokotoff
patent: 4898694 (1990-02-01), Schwartz et al.
patent: 4908358 (1990-03-01), Schreiber
patent: 5206008 (1993-04-01), Loria
patent: 5387583 (1995-02-01), Loria
patent: 5461042 (1995-10-01), Loria
patent: 5635496 (1997-06-01), Daynes et al.
patent: 5811418 (1998-09-01), Daynes et al.
patent: 5859000 (1999-01-01), Dowell et al.
patent: 6187767 (2001-02-01), Araneo et al.
patent: 6667299 (2003-12-01), Ahlem et al.
patent: 7396827 (2008-07-01), Ahlem et al.
patent: 2002/0107233 (2002-08-01), Liao et al.
patent: 2006/0063749 (2006-03-01), Ahlem et al.
patent: 2006/0079492 (2006-04-01), Ahlem et al.
patent: 2007/0129282 (2007-06-01), Ahlem et al.
patent: 2007/0275937 (2007-11-01), Reading et al.
patent: 2008/0015174 (2008-01-01), Reading et al.
patent: 2008/0021006 (2008-01-01), Lardy et al.
patent: 2008/0058301 (2008-03-01), Lardy et al.
patent: WO 00/32201 (2000-06-01), None
patent: WO 01/23405 (2001-04-01), None
patent: WO 01/30802 (2001-05-01), None
patent: WO 02/069977 (2002-09-01), None
patent: WO 2004/019953 (2004-03-01), None
patent: WO 2004/089304 (2004-10-01), None
Pettit et al., Antimicrobial and cancer cell growth inhibitory activities of 3β-acetoxy-17β-(L-prolyl)amino-5α-androstane in vitro, Int. J. Antimicrob. Agents vol. 15 (2000) pp. 299-304.
U.S. Appl. No. 11/835,394, filed Aug. 7, 2007, Lardy et al.
U.S. Appl. No. 11/835,397, filed Aug. 7, 2007, Lardy et al.
Flouret et al, “17-aminoacylamido-5-androsten-3β-ols”J. Med. Chem. 11: 880-882 (1968).
Flouret et al, “17-aminoacylamido steroid antidepressants”J. Med. Chem. 15: 1281-1283 (1972).
Kwiatkowski et al, “A syhthesis of N-substituted β-alanines: Michael addition of amines to trimethylsilyl acrylate”Synthesis946-949 (1989).
Mokotoff et al, “Peptidyl aminosteroids as potential new antiarrhythmic agents”Steroids55: 399-404 (1990).
Pettit et al, “Synthesis of 3β-acetoxy-17β-(L-arginyl-L-arginyl-L-prolyl)-amino-5α-androstane”J. Med. Chem. 10: 145-148 (1967).
Pettit et al, “Structural biochemistry IV. 3β-hydroxy-17β-(L-prolyl)amino-androst-5-ene”Can. J. Chem. 45: 501-507 (1967).
Pettit et al, “Structural biochemistry II. Synthesis of 3β-hydroxy-17β-(L-prolyl)amino-5α-androstane”Can. J. Chem. 44: 2023-2029 (1967).
Vincze et al, “Steroids 54. Aminoacylamidosteroids”Steroids61: 697-702 (1996).
Wheeler et al, “Steroid derivatives of cysteamine and cysteine”Can. J. Chem. 47 160-162 (1969).

Affiliated with

Also associated with

Rating

Therapeutic treatment methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic treatment methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic treatment methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4102308